Ascensia extends PASS program

PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under the program. This is equivalent to an average monthly cost of $16.50 and a total out-of-pocket cost of less than $200 for each entire year of continuous glucose monitoring with Eversense E3, excluding the costs of insertion and removal. “Traditional, short-term CGMs don’t work for everyone, and we are proud to bring a truly unique CGM option in Eversense E3 to people with diabetes,” said Rudy Thoms, vice president, CGM Commercial U.S. at Ascensia Diabetes Care. “We are significantly extending the Eversense PASS program to provide major savings for people in the U.S., beyond when they first try the six-month CGM to their subsequent Eversense E3 CGM systems. We believe that long-term CGMs are the future, and so we are pleased to further improve access to and affordability of Eversense, allowing more people to experience the future today.”  The Eversense PASS Program was first introduced in April 2022 to cover one initial Eversense system, which includes a sensor and transmitter. In May 2023 the $99 offer was extended to cover a whole year of continuous glucose monitoring, through the first two sensor/transmitter combinations, and expanded to include more commercially insured people with diabetes. Following the success of the program, those who are eligible will now be able to access these savings for all further Eversense E3 systems, as long as this program remains in effect.